Abstract
Metabolic syndrome (MS) is a very common medical problem worldwide. It includes obesity, hypertension, hyperglycemia, and abnormal levels of triglycerides and high-density lipoprotein cholesterol. It is closely associated with insulin resistance and may lead to diabetes mellitus, liver diseases, or cardiovascular diseases. Corn silk (CS), a traditional Chinese medicine, has been reported to have multiple beneficial effects, including hypotensive, anti-diabetic, and hypolipidemic properties. This suggests that corn silk could be used to treat or prevent metabolic syndrome. In this review, we will discuss the potential role of corn silk in different components of metabolic syndrome.
Keywords: Corn silk, maydis stigma, metabolic syndrome, hypertension, diabetes, dyslipidemia.
Related Journals
Related eBooks
Related Articles
-
Functional Link Between Adenosine and Insulin: A Hypothesis for Fetoplacental Vascular Endothelial Dysfunction in Gestational Diabetes
Current Vascular Pharmacology Commentary: Diagnostic Validity and Clinical Utility of HbA1c Tests for Type 2 Diabetes Mellitus
Current Diabetes Reviews Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature
Current Diabetes Reviews Recent Updates on Glucokinase Activators for the Treatment of Type 2 Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Glucose Lowering Activity of the Aqueous Extract of Warionia saharae in Normal and Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future
Current Pharmaceutical Design Antihyperglycemic Potential of Incretins Orally Delivered via Nano and Microsystems and Subsequent Glucoregulatory Effects
Current Pharmaceutical Biotechnology Diabetes Mellitus-Cell Transplantation and Gene Therapy Approaches.
Current Molecular Medicine Hypothalamus-Pituitary-Adrenal (HPA) Axis and Metabolic Abnormalities in First-Episode Psychosis
Current Psychiatry Reviews Relevance of Dyslipidaemia and its Consequences in Periodontal Patients with Co-Existing Cardiovascular Disease and Diabetes Mellitus: Therapeutic Targets
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Under Re-organization) Statins in Diabetes Mellitus
Current Pharmaceutical Design Etanercept Improves Cognitive Performance and Increases eNOS and BDNF Expression During Experimental Vascular Dementia in Streptozotocin- induced Diabetes
Current Neurovascular Research The Hot and Potential Targets of Type 2 Diabetes Mellitus Treatment in Recent Decade
Current Drug Targets A Review on the Pharmacology and Toxicology of Steviol Glycosides Extracted from Stevia rebaudiana
Current Pharmaceutical Design Role of Renin Angiotensin System Inhibitors in Cardiovascular and Renal Protection: A Lesson from Clinical Trials
Current Pharmaceutical Design Excessive Matrix Metalloproteinase Activity in Diabetes: Inhibition by Tetracycline Analogues with Zinc Reactivity
Current Medicinal Chemistry Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Current Molecular Medicine Bone Marrow Microenvironment: A Newly Recognized Target for Diabetes- Induced Cellular Damage
Endocrine, Metabolic & Immune Disorders - Drug Targets Liver Disease in Diabetes Mellitus: Potential Therapeutic Value of Vitamin E-Silybin Phytosomal Complex
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization) Analytical Procedures for Secondary Metabolites Determination: Recent Trends and Future Perspectives
Letters in Drug Design & Discovery